SEC Form 10-Q Summary
Important identification note: The supplied filing is for Zeta Acquisition Corp. III, not Kura Oncology, Inc. It covers the quarterly period ended September 30, 2013, and was filed November 14, 2013. The company identifies itself as a development-stage, blank-check and shell company.
Business Context and Reporting Period
Zeta Acquisition Corp. III was formed on November 16, 2007 to identify and complete a business combination with an operating company. It had conducted no active operations other than organizational activities, financing, and searching for an acquisition target. Management reported that it had not identified a target or held discussions with representatives of other entities regarding a business combination.
The unaudited financial statements cover the three and nine months ended September 30, 2013, with comparative periods in 2012, and the cumulative period since inception.
Financial Metrics
| Metric | Three Months Ended September 30 | Nine Months Ended September 30 |
|---|---|---|
| Revenue | $0 | $0 |
| Net loss, 2013 | $6,139 | $18,861 |
| Net loss, 2012 | $6,013 | $17,653 |
| Operating cash flow, 2013 | Not provided for the quarter | $(19,222) |
| Operating cash flow, 2012 | Not provided for the quarter | $(23,634) |
- Net loss since inception was $164,207, consisting primarily of interest expense and legal, accounting, audit, and other professional fees.
- Cash and cash equivalents were $10,580 at September 30, 2013, compared with $4,802 at December 31, 2012.
- Total assets were $14,955, compared with $8,302 at December 31, 2012.
- Total liabilities were $129,162, compared with $103,648 at December 31, 2012.
- Stockholders’ deficit was $114,207 at September 30, 2013, compared with $95,346 at December 31, 2012.
- Stockholders’ notes payable were $110,000, including $25,000 of new unsecured, 6% demand loans during 2013. Accrued and unpaid interest was $15,512.
- Net cash provided by financing activities was $25,000 for the nine months ended September 30, 2013, entirely from stockholder loans.
- Basic and diluted loss per share was reported as $0.00 for the quarter and nine-month period because of rounding; 5,000,000 common shares were outstanding.
- No material off-balance-sheet arrangements were reported.
Material Changes Versus the Prior Comparable Period
- Third-quarter net loss increased modestly to $6,139 from $6,013, while nine-month net loss increased to $18,861 from $17,653.
- Nine-month operating cash usage improved to $19,222 from $23,634.
- Cash increased by $5,778 during the first nine months of 2013, compared with an increase of $1,366 in the comparable 2012 period, primarily because of $25,000 in stockholder financing.
- Stockholder notes payable increased from $85,000 at December 31, 2012 to $110,000 at September 30, 2013.
- Accrued interest increased from $11,298 to $15,512.
- Despite higher cash, the company remained significantly undercapitalized, with current liabilities substantially exceeding current assets.
Guidance, Outlook, Risks, and Unusual Items
Management planned to continue searching for a suitable acquisition candidate and expected to incur costs for SEC reporting and acquisition investigations. The company expected to fund these activities through existing cash, deferred service-provider fees, and additional loans or investments from stockholders, management, or other investors.
Management stated that there was no assurance that additional funding would be available or that the company could satisfy its cash requirements for the next twelve months. The financial statements were prepared on a going-concern basis, but management indicated that continued operations depended on obtaining financing, generating future profitable operations, and completing a suitable business combination.
- The company had generated no revenue since inception and had no operating business.
- Stockholder loans were unsecured and payable on demand, creating near-term liquidity exposure.
- The company had not identified a target and had no assurance that a business combination would occur.
- Any eventual target could be financially unstable, early-stage, or in a high-risk industry; a transaction could also result in substantial dilution and limited diversification.
- The company relied on related parties for continuing funding and used office space and equipment provided by an officer and director at no cost under a month-to-month arrangement.
- Approximately $55,800 of deferred tax assets were fully offset by a valuation allowance because future realization was uncertain.
- No material legal proceedings, unregistered equity sales, defaults upon senior securities, or material changes in internal controls were reported. Management concluded disclosure controls were effective.
Investor Verification Points
- Verify the issuer identity: the filing names Zeta Acquisition Corp. III, not Kura Oncology, Inc.
- Confirm the company’s ability to continue as a going concern given $10,580 of cash, $129,162 of liabilities, and demand notes payable to stockholders.
- Review the terms, maturity, interest rate, and related-party status of the $110,000 stockholder notes and $15,512 of accrued interest.
- Determine whether any business combination was identified or completed after September 30, 2013.
- Assess potential dilution and transaction terms associated with any future reverse merger or equity financing.
- Reconcile the filing’s historical financial information with the correct company and reporting period before relying on the figures for investment analysis.